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Seventy-two long-surviving liver transplant recipi-
ents were evaluated prospectively, including a base-
line allograft biopsy for weaning off of immunosup-
pression. Thirteen were removed from candidacy 
because of chronic rejection (n=4), hepatitis (n=2), pa-
tient anxiety (n=5), or lack of cooperation by the local 
physician (n=2). The other 59. aged 12-68 years, had 
stepwise drug weaning with weekly or biweekly moni-
toring of liver function tests. Their original diagnoses 
were PBC (n=9), HCC (n=I), Wilson's disease (n=4), 
hepatitides (n=15), Laennec's cirrhosis (n=I), biliary 
atresia (n=16), cystic fibrosis (n=1), hemochromatosis 
(n=I), hepatic trauma (n=ll, alpha-I-antitrypsin defi-
ciency (n=9), and secondary biliary cirrhosis (n=1). 
Most of the patients had complications of long-term 
immunosuppression, of which the most significant 
were renal dysfunction (n=8), squamous cell carci-
noma (n=2) or verruca vulgaris of skin (n=9), osteopo-
rosis and/or arthritis (n= 12), obesity (n=8), hyperten-
sion (n= Ill, and opportunistic infections (n=2). When 
azathioprine was a third drug, it was stopped first. 
Otherwise, weaning began with prednisone, using the 
results of corticotropin stimulation testing as a guide. 
If adrenal insufficiency was diagnosed, patients re-
duced to <5 mg/day prednisone were considered off of 
steroids. The baseline agents (azathioprine, cyclospo-
rine, or FK506) were then gradually reduced in 
monthly decrements. Complete weaning was accom-
plished in 16 patients (21.1%) with 3-19 months drug· 
free follow-up, is progressing in 28 (41.4%), and failed 
in 15 (25.4%) without graft losses or demonstrable loss 
of graft function from the rejections. This and our pre-
vious experience with self-weaned and other patients 
off of immunosuppression indicate that a significant 
percentage of appropriately selected long-surviving 
liver recipients can unknowingly achieve drug-free 
graft acceptance. Such attempts should not be contem-
plated until 5-10 years posttransplantation and then 
only with careful case selection. close monitoring, and 
prompt reinstitution of immunosuppression when 
necessary. 
Lifetime immunosuppression has been a presumed neces-
sity after clinical whole-organ transplantation. However, we 
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have suggested elsewhere that liver allograft acceptance 
without a need for maintenance immunosuppression may 
have been accidentally achieved more often than realized (1). 
The recently proposed concept that donor leukocyte migra-
tion and long-tenn microchimerism is the basis of allograft 
acceptance (2) would account for the slow evolution of the 
self-sustaining drug-free tolerance that has been most fre-
quently seen in, but not confined to, liver recipients (3). 
The possibility of drug weaning had previously been dem-
onstrated by 6 noncompliant liver recipients who were found 
in April 1992 to have successfully discontinued all medica-
tions from 5 to 13 years previously (1), and by 5 more with 
EBV-associated B cell lymphomas whose drugs had been 
stopped 6 months to 8 years posttransplantation with subse-
quent drug-free survival for 0.5 to 2.8 years (4). The present 
prospective weaning study did not include these 11 earlier 
recipients, all of whom continue to be well with 1 Y2 to 2Y2 
more years of follow-up. 
We describe here a prospective trial of drug weaning of 59 
more long-surviving liver recipients, all of whom had compli-
cations of chronic immunosuppression. All patients reported 
with complete drug discontinuance have been observed sub-
sequently for 6.5 to 22.5 months. 
MATERUUS AND METHODS 
Case material. Between June 1992 and March 1994,72 patients 
were evaluated for the wearung protocol. Candidacy criteria were: ( 1) 
::5 yr post-transplantation: (2) ~O yr without episode of rejection: (3) 
history of medical compliance: (4) evidence of complicatione related 
to chronic immunosuppressive therapy; (5) primary physician coop-
eration; and (6) baseline liver biopsy 8howing no evidence of rejection 
or severe hepatic disease. Thirteen of the 72 patients were with-
drawn from the candidacy list because of biopsy evidence of acute or 
chronic rejection (n=4), severe hepatitis on biopsy (n-2), patient 
anxiety (n=5), and refuaal of cooperation by primary physician 
(n =2). The remaining 59 included 20 who were 12-20 yean old when 
weaning was started, and 39 who were 21-68. 
Baftline immunoBuppress,on. The drugs regimens from which 
weaning occurred were: azathioprine and prednisone (AZAIPRED) 
(n"lO>, cyclo8porine and prednisone ICsAlPREDl (n-19), cydospo-
rine and azathioprine ICsAJAZA) (n=31. cyclosporine. azathioprine. 
and prednisone ICsAJAZNPREDl (n= 12), cyclosporine alone (CBA) 
(n=9) and tacrolimua (FK506. Prograt) (n-6). The 6 patients on . 
tacrolimua had been converted from other regimene earlier in their 
coune. 
Weaning protocol. If AZA was part of triple therapy, it waa weaned 
before beginmng prednisone reduction. but if it wu the principal 
immun08uppressant It was weaned in the same way as the other 
baseline drugs (see below). Patients still receiving prednisone were 
bellUD with a OR-SM~ lurold reduCtlon. In the event of hepatocellu· 
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TABLE 1. Total patients weaned (n=59) 
OLTX Diapoei. Bueline Predominant Preeent Lab.: Prnent No. UDlDUDOIuppnMUrion Pre_aning complications AST/ALT/GGTP 8tatul 
0133 Hepatitis B AZAIPRED Hepatitis. warta 22129/199 Off 
0046 Biliary atresia AZAIPRED Osteoporosis. warts 271311· Weaning 
0140 Biliary atresia AZAIPRED Cholangitis. warts 241191119 Rejection 
0064 Biliary atresia AZAIPRED Squamous cell skin CA. warts 63149/98 Off 
0281 Biliary atresia. Alagilles syn. AZAIPRED EBV infection. warts 27131116 Off 
0325 Biliary atresia. Alagilles syn. AZAIPRED EBV infection. warts 311261· Off 
0166 PBC· AZAIPRED C~infectionsKwarts 35130/71 Rejection 
0144 PBC AZAIPRED Osteoporosis 32133124 Off 
0042 Wilson's disease AZAIPRED Squamous, basal cell skin CA. warts 49/47/47 Off 
0105 PNC·C AZAIPRED Obesity 37131154 OtT 
0190 Biliary atresia CsA/PRED 22130/55 Rejection 
0666 Non A, non B hepatitis CsA/PRED HTN,RD 381231171 Weaning 
0194 HCC CsA/PRED HTN.RD 451361110 Rejection 
0173 Secondary biliary cirrhosis: CsA/PRED Basal cell CA 49129/481 Rejection 
trauma 
0210 CAH, autoimmune CsA/PRED Ulcerative colitis. HTN. sclerosing 38136141 Weaning 
cholangitis, anemia. RD. warts 
0488 Hepatitis B CsA/PRED 42132128 Rejection 
0171 CAH CsA/PRED Warts. osteoporosis 64156146 Weaning 
1464 PNC·E CsA/PRED Steatosis. RD. HTN 28/24145 Weaning 
0605 PNC·C,? CAH CsA/PRED Osteoporosis. HTN. RD. warts 24128123 Rejection 
0177 Cirrhosis: postnecrotic, Non A. CsA/PRED 23127/82 Rejection 
non B hepatitis 
0476 Cystic fibroSIS CsA/PRED Pulmonary infection 49/33175 Weaning 
0450 Wilson's disease CsA/PRED Warts 33126127 Rejection 
0314 Biliary atresia CsA/PRED Warts 99/66/· Weaning 
1182 Hepatitis CsA/PRED Obesity 20124155 Weaning 
0349 Cirrhosis: cryptogenic CsA/PRED RD.HTN 29132120 Weaning 
0535 A·1·A CsA/PRED Warts 22137/59 Weaning 
0273 A-1-A CsA/PRED 13/24139 Weaning 
1713 Hepatitis B. FHF CsA/PRED Obesity. Osteoporosis 42137/40 Weaning 
0646 Wllaon's disease CsA/PRED 35135132 Weaning 
0142 A-1·A CsAlAZA 'lUberculosis 22128118 Rejection 
0331 PBC CsAlAZA Osteoporosis. HTN. RD 9121165 Weaning 
1535 A·1-A CsAlAZA 48146119 Weaning 
0592 PBC CsAlAZAIPRED Osteoporosis 30125143 Weaning 
2113 Cirrhosis: cryptogenic CsAlAZAIPRED Cycloneuropathy. hemosiderosis. 45137/· Rejection 
hemodialysis. HTN 
0440 A·1·A CsAlAZAIPRED HTN. osteoporosis 26/30/69 Weaning 
1308 Hepatitis C CsAlAZAIPRED Pulmonary infection. fatty liver, 111183/87 Off 
steatosis 
0235 PBC CsAlAZAIPRED Warta. osteoporosis 551-150 Weaning 
0297 PBC CaA/AZAIPRED Osteoporosis 7/14116 Rejection 
0977 Hemochromatosis CsAlAZAIPRED TB infection 15123116 Rejection 
1604 Biliary atresia CaA/AZAIPRED Recurrent CMV 83179/30 Weaning 
0289 Non A. non B hepatitis CsAlAZAIPRED Warts 38148171 Weaning 
0323 A·1-A CsAlAZAIPRED Recurrent C~ 321511196 Weaning 
0531 PBC CsAlAZAIPRED Osteoporosis 38140121 Weaning 
0345 A·1·A CsAlAZAIPRED Anal warta 46140121 Weaning 
0223 PBC CsA Osteoporosis 13118110 Rejection 
0202 Wilson's disease CsA 59/591256 Off 
1215 Halothane hepatitis CsA Warta 17123126 Weaning 
0516 PBC CsA C~ infection 351311121 Weaning 
0191 Biliary atresia CsA Recurrent mucocutaneous 331351· Off 
fungal infections 
0717 A·1·A CsA Warta 251231· Weaning 
0355 Biliary atresia CsA EBV infection 47/-153 Off 
0189 Biliary atresia CsA HTN 33139/9 Off 
0447 Biliary atresia CsA 39137/· Weaning 
2134 Biliary atresia. Alagilles syn. FK506 EBV infection 48137121 Weaning 
3011 Biliary atresia FK506 Herpes stomatitis 24144/12 Rejection 
0474 Hepatitis B FK506 Steroid intolerance 13412201453 Off 
2743 Biliary atresia FK506 HTN.RD 491261· Off 
2621 Biliary atresia FK506 Steroid intolerance 7514219 Off 
3039 A·1·A FK506 Epigastric pain. peptic ulcer of pylorus. 54148117 Off 
pylOric bulb 
• HTN • hypertension; RD = renal dysfunction; PNC = poatnecrotic cirrhosis; PBC = primary biliary cirrhosis; HCC = hepatocellular 
, carcinoma: A-I·A .. alpha 1 antitrypsin; PNC·C = postnecrotic cryptogenic cirrhosis. 
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FIGURE 1. (Thp) Changes in AST. ALT vs. days postweaning for the 
rejection group. Enzyme values are In international unitsIL. Indi-
vidual boxes: (iine) = median: (boxes) = interquartile range; (bars) = 
true range. (Bottom) Changes in GGTP vs. days postweaning for the 
rejection group. Enzyme values are in international unitsIL. Indi-
vidual boxes: lline) = median; (boxes) = interquartile range; (bars) = 
true range. 
lar enzyme elevation. no further changes were made until the en-
zymes stabilized. Further decrements in prednisone were at one-
month intervals. Corticotropin stimulation testing was used to detect 
adrenal cortical insufficiency before complete steroid withdrawal. 
Corticotropin (,25 mg! was administered intravenously after obtain-
ing a baseline serum cortisol level. Serum cortisol was then meas-
ured at 30 and 60 min post-cortlcotropm administration (5 l. Pa-
tients with normal adrenocortical function responded to stimulation 
WIth >7 Ilgldl increase in serum cortisol. 
Reduction of the baseline immunosuppressive agents. CsA. AZA. 
and tacrolimus (FK506. Prograf) also were conSIdered every month. 
CsA was reduced by 10-25%/month until blood levels were <50 nglml 
for 3 months and then by 50%/month until cessation. A similar pro-
tocol was used for FK506. 
Baseline enzyme measurements of AST. ALT. GGTP. and serum 
bilirubin were performed weekly or bIweekly between the monthly 
decision points. as well as CsA and FK506 trough levels. Enzyme 
elevations or patient symptoms tnggered an Increased frequency of 
liver function tests. and a judgment about restoration of immuno-
suppression. In reaclung a deciSIon. the prewearung biopsy was m-
valuable for companson with subsequent ones. 
Chimensm studies. Microchimensm studies had been performed 
previously on 13 of the 59 patients. all of whom had donor cells or 
DNA demonstrated In peripheral tlaaues. or blood by the detection of 
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FIGURE 2. (Thp) Changes in AST. ALT. and GGTP vs. days postwean-
ing for the enzyme elevation group. Enzyme values are in interna-
tional unitsIL. Individual boxes: dine! = median: (boxes) = inter-
quartile range; (bars) = true range. 1B0ttom! Changes in GGTP vs. 
days postweaning for the enzyme elevation group. Individual boxes: 
(\ine) = median: lboxes! = Interquartile range; ,bars! = true range. 
Y chromosome in female patient recipients of male donor organs, or 
by the detection of donor specific HLA alleles--using cytostaining 
and polymerase chain reaction (PCRl techniques U, 2). Because 
chimerism was mvariably demonstrable in all of our long-surviving 
liver and kidney allograft reCipients. It was assumed to be present in 
the rest of the cases of the present study and these tests were not 
performed. 
in-lJitro testing: homozygous tYPIng ceLLs (HTC). Twenty-six pa-
tients were studied. To assess the development of donor-specific hy-
poreactivity, their peripheral blood mononuclear cells (PBMCI were 
tested in standard mixed lymphocyte reaction (MLRl against a panel 
of homozygous tYPing cells mTCI as preViously described (6l. These 
stimulator cells were selected based on their homozygosity for 
HLA-DR and in each assay HTCs for 7 different Ow specificities were 
included. with 2-3 HTCs per speCificity. Each responder was tested 
with HTCs that identified ·selr specificities. HTCs that defined the 
donor DR type. and unrelated control third party stimulators. The 
results were expressed as double normalized values (DNVsl. Im-
mune responsiveness was evaluated through mitogen induced pro-
liferation. Isolated mononuclear cells from patients heparinized 
blood were cultured. Proliferation 1I.e .. responsiveness) was asseued 
by 3H-thyuudine uptake after mduction \Imh phytohemagglutinin 
(PHAI and concanavalin A (Con AI. 
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TABLE 2. Patients haVln!! enzvrne elevations without reJection (n=2Q) 
OTNo. 
2134 
0666 
0592 
0440 
1308 
0202 
0235 
0064 
0042 
0105 
1464 
1604 
0289 
0331 
0476 
1215 
0314 
0474 
0516 
1182 
" NA = not available. 
Biliary atresia. Alagilles syn. 
Non-A. Non-B 
PBC 
A-l-A 
Hep.C 
Wilson's disease 
PBC 
Biliary atresia 
Wilson's disease 
PNC-C 
PNC-E 
Biliary atresia 
Non-A. Non-B 
PBC 
Cvstic fibrosis 
H'alothane hepatitis 
Biliary atresia 
Hep. B 
PBC 
Hep. 
TABLE 3. EtTects of immunosuppressIOn reductIOn 
Weaned patients Outcome 
Number Improved No Complication 
change 
Infections 7 5 2 
Tumor 2 (SCC) I" 1 
Obesity 1 1· 
Hypertension 2 
Osteoporosis 1 
Steroid intolerance 3 3 
• Dramatic improvement. 
RESULTS 
Worse 
Outcome of weaning. Failure of Weaning. After a follow-up 
of 6.5 to 22.5 months (mean 15 months) 15 (25.1%) of the 59 
patients have had a diagnosis of rejection (Table 1), Three of 
the 15 were treated without pathologic documentation of re-
jection and were subsequently placed back on the weaning 
protocol. There were no graft losses. or examples of jaundice. 
All liver functions eventually returned to their preweaning 
values. The enzyme data and summarized in Figure 1. 
Rejection in the 12 biopsy-confirmed cases (AJDl was di-
agnosed by the presence of portal triad cellular infiltrates 
causing duct damage. duct loss. or central venulitis. Two 
patients had histologic classification of moderate-to-severe 
rejection. and the 2 were converted to FK506. The other 10 
rejections were classified as minimal-to-mild. When rejection 
was diagnosed. it was treated with 1 g methyl prednisolone 
and a 6-day prednisone cycle. starting at 200 mg on the first 
dav and ending at 10 mg/day. Two patients were converted 
fr~m CsA to FK506. One of these patients. who also required 
additional pulse steroid therapy. developed herpes keratitis 
that responded to acyclovir therapy and reduction of immu-
nosuppression. This was the only serious complication in the 
trial. 
Weanmg complete or In progress. Sixteen patients (27.1%) 
are off medications. including 2 kept on <5mg of prednisone 
due to an unresponsive corticotropin stimulation test. The 
other 28 (47.4%) are still at various phases of weaning. 
Status LI veT bIOpSIes 
Wearung NAG 
Weaning (No ACR) Lobular reactivity 
Weaning (No ACR) Lobular reactivity 
Weaning NA 
OtT Minimal lobular reactivity 
OtT Large duct obstruction 
Weaning NA 
OtT (No ACR) Re!!enerative hyperplasia 
?Drug effect 
OtT NA 
OtT Lobular reactivity 
Weaning NA 
Weaning NA 
Weaning NA 
Weaning Lobular reactivity 
Weaning Minimal changes (normal) 
Weaning NA 
Weaning NA 
OtT Hepatitis 
Weaning Lobular reactivity 
Weaning Hepatitis 
Twenty patients. including some fully weaned and still 
being weaned. had enzyme elevations that spontaneously re-
turned to normal despite further weaning or drug discontinu-
ance (Fig. 2)_ The enzyme patterns were similar to those in 
the weaning failure group (compare with Figure 1). In those 
caK~es in which biopsies were obtained. the histopathologic 
findings were nonspecific. including the lobular reactivity or 
inflammation that is not diagnostic of rejection (7) (Table 2). 
Effect on preweaning complications. The most consistent 
improvement was the involution of verrucous warts. One 
patient with squamous cell carcinoma of the skin had dra-
matic improvement with virtual disappearance of lesions 6 
months after completion of weaning. Preexisting hyperten-
sion and renal dvsfunction were not affected (Table 3). 
Outcome vers~s prior immunosuppression. There was a 
high rate of weaning failure in patients previously treated 
with triple-or double-drug cyclosporine-based immunosup-
pression. Good results were obtained if prior treatment was 
with cyclosporine or with azathioprineJpredrusone (Table 4). 
Proven chimerism versus outcome. Seven of the 13 patients 
proved in April-4une 1992 to have donor leukocyte chimer-
ism (1) have since been successfully weaned. Two more are 
still in the process, and 5 were returned to immunosuppres-
sion either because of biopsy evidence of rejection (n=4) or 
unconfirmed suspicion of this diagnosis (n = n 
Homozygous typing cells assay. Results from samples 
drawn before or close to the onset of wearung were equivocal 
in 10 of the 26 patients due to low reactivity to all panels or 
madequate sampling. making the test imposslble to inter-
pret. Of the other 16. 8 were reactive to the whole panel. Five 
have had episodes of rejection and 3 are still weaning (Table 
51. 
Eight patients were hyporeactive for donor-specific DR an-
tigen only. Five of this group are off medications. 1 is still 
being weaned. and 2 failed weaning (Table 5l. 
DISCUSSION 
The rationale for this trial was based in part on the previ-
ous observation m early 1992 that 15% of our liver recipients 
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TABLE 4. Present status of patients by baseline immunosuppression" 
Mean yean after OLTX Rejection group Off group Weaning group 
AZAIPREDb 
CaAlPREDb 
CsAlAZA 
CsAlAZAIPRED 
CsA 
16.0:4.3 2 7 1 
12 
2 
8 
4 
1 
10.2:2.7 7 0 
10.9:5.1 1 0 
8.6:2.3 3 1 
9.7:2.8 1 4 
FK506 5.4: 1.8 1 4 
Thtal 
• Mean years posttranspiant of total population (n=59): 10.25:4.3. 
b X2=6.77. P<O.Ol. and Fisher's exact test P=<O.OI. 
TABLE 5. Homozygous typing cell assay results (n=26)". 
A. Reactive 
OTNo. Baseline Statu. Wean-present immunoauppreaaion atate(daya)b 
142 CsA/AZA Rej. 105 
162 AZAIPRED Rej. 170 
166 AZAIPRED Rej. 142 
223 CsA Rej. 154 
235 CaAlPRED/AZA Weaning 480 
297 CaAlPRED/AZA Rej. 66 
1713 CsA Wearung 330 
2134 FK506 Weaning 450 
B. Hyporeactive 
B ... line Interval DR OTNo. immunoauppreuion Statu. Wean-present antlgen state (daya)' (donor) 
064 AZAIPRED Off 109 DR-4 
189 CsA Off 202 DR-7 
191 CsA Off 294 DR-3 
1308 CaAlPRED/AZA Off 84 DR-6 
281 AZAIPRED OtT 75 DR-7 
194 CaAlPRED Rej. 56 DR-5 
1215 CsA Weaning 420 DR-' 
977 CaAlPRED Rej. 348 DR-4 
• The assay was performed in 10 additional patients with equivo-
cal results = (Jow or unresponsive to all panels including self and 3rd 
party). 
b Mean of all rejection patients 146:94.5. 
< Mean of all off patients 192: 163.4. 
followed >10 years had discontinued all medications 5 to 13 
years previously without developing rejection (l). With 2Y2 
more years of follow-up, these 6 recipients. who for the most 
part had reached a drug-free status by noncompliance. are 
still well with 2Y2 more years follow-up. A further collection of 
5 children whose physician-directed drug discontinuance .5 
to 8 years posttransplantation was prompted by the develop-
ment of Epstein-Barr-associated B cell lymphomas (4) con-
tinue to be stable and now have been drug-free for from 1 or 
to 3.3 years. 
The prospective weaning trial herein reported has con-
firmed our suspicion that many long-term survivors after 
liver transplantation no longer need chronic immunosup-
pression at the prescribed levels. if at all. One-fourth of the 
patients entered have been able to discontmue immunosup-
pression altogether. half are still weaning without complica-
tions. and only a quarter have failed the effort. No hepatic 
grafts have been lost and none has suffered measurable dam-
age. The only significant complication was in a patient who 
developed readily treated herpes keratitis. In 2 examples of 
histopathologically severe rejection. a safety net was pro-
15 16 28 
vided by the "rescue" capabilities ofFK506 (8) to which the 
patients were converted. 
The need for close and continuance medical surveillance 
was evident. All of the rejections were signaled without the 
occurrence of jaundice by rises in the transaminase levels 
and in the canalicular tests of which the GGTP is the most 
specific. Confirmatory allograft biopsies were of the utmost 
importance for management decisions because enzyme rises 
during weaning were seen with equal frequency in allografts 
with and without evidence of rejection. There was no clear 
explanation for the transient enzyme increases in patients 
whose weaning was not interrupted. One possibility was that 
there was an unapparent and self-resolving rejection. An-
other might have been the loss during drug withdrawal of the 
hepatotrophic effects of either cyclosporine (9) or FK506 (10). 
Two of these nonrejecting patients have had waxing and wan-
ing of the enzyme activity during further weaning or drug 
stoppage. 
Although it is too soon to be confident about the safety of 
the weaned patients, the demonstration of allograft stability 
in the previously reported drug-free patients for as long as 15 
years is reassuring. In the presently reported prospective 
study, the peak risk appeared to have been passed by the 
sixth month. Early dividends of discontinuance of immuno-
suppression have already been seen, most frequently the in-
volution of benign as well as malignant skin lesions. Disap-
pointingly, there has been no improvement in preexisting 
arterial hypertension or renal dysfunction. 
The subgroup of 13 patients with previously documented 
chimerism was of special interest. We have emphasized fre-
quently our belief that this chimerism is a cardinal require-
ment for allograft acceptance and for the potential eventual 
evolution of donor specific nonreactivity (tolerance) but that 
it is not synonymous with either outcome. The proposition as 
originally stated was that "Clinical success-tolerance or 
graft acceptance-means that a characteristic lymphoid and 
dendritic cell chimerism has been introduced, which may be 
stable either without further treatment or only when contin-
ued immunosuppression is provided; an unstable graft and 
its migrated cells may either be rejected or cause GVHD" (2). 
The heterogeneity of results from weaning in these 13 cases 
conformed entirely with this central hypothesis. Although 9 
of the 13 liver recipients have been able to stop drugs (n = 7) 
or are successfully weaning (n=2). the onset of rejection re-
quired resumption of immunosuppression in the other 4. 
As discussed in detail elsewhere (11 ). acceptance of whole-
organ allografts and the achievement of a drug-free state are 
in fact mirror image events to those occurring after successful 
bone marrow transplantation in cytoablated recipients. The 
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f~K 
" , 
--
January 27, 1995 RAMOS ETAL. 217 
fundamental difference is that the trace leukocyte population 
in the David/Goliath cell relationship following whole-organ 
transplantation is donor rather than recipient. with the ob-
vious implication that the principal risk is rejection rather 
than GVHD. Using this two-way paradigm of transplanta-
tion immunology, it is easy to understand the lengthy periods 
of immunosuppressive coverage that are usually necessary 
before a drug-free state can evolve. When bone marrow trans-
plantation is from MHC-matched donors. continuous immu-
nosuppression is frequently required for a year or more, and 
when there are 1 to 3 HLA allele mismatches, a period of 5 
years or longer is needed before drugs can be stopped. 
The liver transplant recipient has delineated an even more 
protracted time frame for solid-organ recipients of mis-
matched whole-cadaver organs (12). The risk in liver recipi-
ents of weaning attempts too early, too abruptly, or without 
frequent testing of allograft function have been described by 
. Sanborn et al. (13) in a series of patients weaned from a 
cyclosporine-based triple-drug therapy. Moderate-to-severe 
rejection was frequently encountered in this series of 12 
cases. leading to secondary complications after renewal of 
high-dose immunosuppression and eventually 2 deaths. The 
difficulty of weaning from cyclosporine when it was part of a 
triple-drug regimen also was noted in our experience. 
Although this study was concerned only with liver al-
lografts. we believe that the same trends can be found with 
other whole organs if these are systematically looked for. Five 
of our long-term recipients of living-related kidneys (not 
twins) have been off of immunosuppression for 1,1.7,14,28, 
and 29 years (3). However, the lower density of chimerism in 
kidney and heart recipients undoubtedly makes weaning 
more hazardous than in the recipient of the inherently toler-
ant liver, and consequently this has been attempted only 
when there are immunosuppression-associated life-threaten-
ing complications (14). 
The inability to accurately predict which patients can be 
successfully weaned means that all such attempts are on a 
trial-and-error basis, particularly when the donor leukocytes 
are unavailable for prognostic in vitro testing. Because we 
did not have donor lymphoid tissue in any of the liver wean-
Ing cases. we attempted to test recipient responsiveness to 
cells homozygous to the donor DR antigens as described by 
Reinsmoen et al. (6). A trend was noted of antidonor respon-
siveness in the rejection group and nonresponsiveness in pa-
tients successfully weaned, but this was imprecise. It has 
been pOinted out before that even in vitro testing with donor 
cells does not correlate well with tolerance in animals (15-
17) and humans (18,19), This fundamental limitation of in 
vitro testing, rather than inherent imperfections in the sur-
rogate technique of homozygous typing, shows that more pre-
dictive methods need to be developed. 
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